01P Stock Overview Provides clinical research-based drug and medical device development services in North America, Europe, and Asia. More details
Rewards Risk Analysis No risks detected for 01P from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Medpace Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Medpace Holdings Historical stock prices Current Share Price US$324.70 52 Week High US$418.70 52 Week Low US$255.00 Beta 1.36 1 Month Change 2.04% 3 Month Change 9.55% 1 Year Change 15.96% 3 Year Change 67.37% 5 Year Change 344.79% Change since IPO 1,154.44%
Recent News & Updates
Investor sentiment improves as stock rises 16% Nov 07
Third quarter 2024 earnings released: EPS: US$3.11 (vs US$2.30 in 3Q 2023) Oct 22
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Oct 22
Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024 Sep 26
New minor risk - Share price stability Jul 23
Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023) Jul 23 See more updates
Investor sentiment improves as stock rises 16% Nov 07
Third quarter 2024 earnings released: EPS: US$3.11 (vs US$2.30 in 3Q 2023) Oct 22
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Oct 22
Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024 Sep 26
New minor risk - Share price stability Jul 23
Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023) Jul 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Jul 23
Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024 Jun 27
Executive Vice President of Operations recently sold €2.8m worth of stock Jun 10
Chairman & CEO recently sold €3.5m worth of stock May 30
Chairman & CEO recently sold €6.3m worth of stock May 02
New minor risk - Share price stability Apr 24
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 23
First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023) Apr 23
Medpace Holdings, Inc., Annual General Meeting, May 17, 2024 Apr 04
Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024 Mar 29
Chairman & CEO recently sold €23m worth of stock Feb 23
Investor sentiment improves as stock rises 18% Feb 20
Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022) Feb 13
Executive Vice President of Operations recently sold €3.5m worth of stock Dec 19
Now 21% undervalued Dec 06
Chairman & CEO recently sold €20m worth of stock Nov 17
Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024 Oct 25
New minor risk - Share price stability Oct 25
Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022) Oct 24
Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023 Sep 27
Now 20% undervalued Sep 19
Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022) Jul 25
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023 Jul 25
Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023 Jul 06 Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index
Now 21% undervalued Jun 22
First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022) Apr 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023 Feb 14
Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021) Feb 14
Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023 Jan 05
Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board Jan 04
CFO & Treasurer recently sold €440k worth of stock Nov 18
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021) Oct 26
Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares. Oct 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023 Oct 25
Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022 Sep 28
Chairman & CEO recently bought €15m worth of stock Sep 23
Chairman & CEO recently bought €10m worth of stock Sep 14
Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021) Jul 26
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Jul 26
Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022 Jul 08
Insufficient new directors Jun 02
First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021) Apr 27
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022 Apr 26
Medpace Holdings, Inc., Annual General Meeting, May 20, 2022 Apr 07
Investor sentiment improved over the past week Mar 19
Lead Independent Director recently bought €64k worth of stock Feb 23
Investor sentiment deteriorated over the past week Feb 22
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022 Feb 15
Now 22% undervalued after recent price drop Jan 26
Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020) Oct 26
Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020) Jul 28
First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020) Apr 28
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021 Apr 27
Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021 Mar 11
Executive Vice President of Operations recently sold €859k worth of stock Mar 06
Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019) Feb 19
Revenue beats expectations Feb 19
New 90-day high: €121 Feb 05
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Jan 28
Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021 Jan 06
New 90-day high: €109 Dec 02
Third quarter earnings released Oct 27
Third-quarter earnings released: Revenue beats expectations Oct 27 Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)
Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020 Sep 04
New 90-day high - €110 Sep 03
New 90-day high - €102 Jul 28
Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index Jul 05 Shareholder Returns 01P DE Life Sciences DE Market 7D 0.7% 0.2% -0.2% 1Y 16.0% -5.4% 7.0%
See full shareholder returns
Return vs Market: 01P exceeded the German Market which returned 7% over the past year.
Price Volatility Is 01P's price volatile compared to industry and market? 01P volatility 01P Average Weekly Movement 6.2% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 01P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 01P's weekly volatility (6%) has been stable over the past year.
About the Company Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Show more Medpace Holdings, Inc. Fundamentals Summary How do Medpace Holdings's earnings and revenue compare to its market cap? 01P fundamental statistics Market cap €10.22b Earnings (TTM ) €351.46m Revenue (TTM ) €1.99b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 01P income statement (TTM ) Revenue US$2.07b Cost of Revenue US$678.86m Gross Profit US$1.39b Other Expenses US$1.03b Earnings US$365.57m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 12:35 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medpace Holdings, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Eric Coldwell Baird Ishan Majumdar Baptista Research Erin Wilson Wright Credit Suisse
Show 17 more analysts 
